Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Sales and Divestitures (2020 - 2022)

Cullinan Therapeutics (CGEM) has 3 years of Gains from Sales and Divestitures data on record, last reported at $46000.0 in Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures fell 83.27% year-over-year to $46000.0; the TTM value through Dec 2022 reached $46000.0, down 83.27%, while the annual FY2022 figure was $46000.0, 83.27% down from the prior year.
  • Gains from Sales and Divestitures reached $46000.0 in Q4 2022 per CGEM's latest filing, down from $275000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $275000.0 in Q4 2021 and bottomed at $46000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 3 years is $149786.0, with a median of $128358.0 recorded in 2020.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 114.24% in 2021, then crashed 83.27% in 2022.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $128358.0 in 2020, then surged by 114.24% to $275000.0 in 2021, then plummeted by 83.27% to $46000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $46000.0 in Q4 2022, $275000.0 in Q4 2021, and $128358.0 in Q4 2020.